D. Lazarus

发表

A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis.

C. D. Thompson, G. Hannig, S. Bernier, 2004, Proceedings of the National Academy of Sciences of the United States of America.

CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer

M. Wicha, S. Eliasof, S. Clouthier, 2015, Breast Cancer Research and Treatment.

Insulin-like growth factor-1 activity is inhibited by interleukin-1 alpha, tumor necrosis factor-alpha, and interleukin-6.

L. Moldawer, S. Lowry, D. Lazarus, 1993, Lymphokine and cytokine research.

Influence of hypercortisolemia on the acute-phase protein response to endotoxin in humans.

L. Moldawer, S. Lowry, S. Coyle, 1992, Surgery.

Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer

M. Birrer, R. Kerbel, S. Eliasof, 2014, Clinical Cancer Research.

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis.

P. Elliott, J. Davis, J. Davis, 1998, Proceedings of the National Academy of Sciences of the United States of America.

The lack of an effect by insulin or insulin-like growth factor-1 in attenuating colon-2-mediated cancer cachexia.

S. Lowry, G. Strassmann, T. Kambayashi, 1996, Cancer letters.

A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.

A. Goldberg, P. Elliott, L. Dick, 1999, American journal of physiology. Endocrinology and metabolism.

A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway.

A. Goldberg, P. Elliott, L. Dick, 1999, The American journal of physiology.

Impact of exogenous growth hormone on host preservation and tumor cell-cycle distribution in a rat sarcoma model.

L. Moldawer, S. Lowry, C. S. Rock, 1991, The Journal of surgical research.

Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.

R. Kerbel, S. Eliasof, Christina R. Lee, 2016, Cancer research.

Cachexia and the acute‐phase protein response in inflammation are regulated by interleukin‐6

L. Moldawer, S. Lowry, H. Oldenburg, 1993, European journal of immunology.

Interleukin 1 binding to its type I, but not type II receptor, modulates the in vivo acute phase response.

L. Moldawer, S. Lowry, H. Oldenburg, 1995, Cytokine.

Vesnarinone inhibits immune-mediated but not Fas (CD95) agonist-mediated hepatic injury.

G. Strassmann, C. Jacob, H. Baumann, 1997, International journal of immunopharmacology.

Endogenous IL-10 protects mice from death during septic peritonitis.

T. van der Poll, L. Moldawer, S. Lowry, 1995, Journal of immunology.

Involvement of 26-kDa cell-associated TNF-alpha in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor.

J. Vauthey, L. Moldawer, C. Edwards, 1997, Journal of immunology.

Interleukin-1α (IL-1α) and Tumor Necrosis Factor α (TNFα) Regulate Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Levels and mRNA Abundance In Vivo and In Vitro*

L. Moldawer, S. Lowry, C. Benbassat, 1999 .

Interleukin-1 alpha (IL-1 alpha) and tumor necrosis factor alpha (TNF alpha) regulate insulin-like growth factor binding protein-1 (IGFBP-1) levels and mRNA abundance in vivo and in vitro.

L. Moldawer, S. Lowry, C. Benbassat, 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

Endogenous interleukin-10 protects against death in septic peritonitis in mice

L. Moldawer, S. Lowry, M. Goldman, 1994 .

Proteasome inhibitors: a novel class of potent and effective antitumor agents.

E. Sausville, P. Elliott, J. Johnson, 1999, Cancer research.

Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458.

C. D. Thompson, G. Hannig, S. Bernier, 2006, International journal of oncology.

Tumor Selective Silencing Using an RNAi-Conjugated Polymeric Nanopharmaceutical.

S. Eliasof, S. Svenson, S. Tripathi, 2016, Molecular pharmaceutics.

Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle

Mark E. Davis, J. Zuckerman, Y. Yen, 2013, Proceedings of the National Academy of Sciences.

An inhibitor of methionine aminopeptidase type-2, PPI-2458, ameliorates the pathophysiological disease processes of rheumatoid arthritis

C. D. Thompson, A. Rogers, G. Hannig, 2008, Inflammation Research.

Insulin-like growth factor I preserves host lean tissue mass in cancer cachexia.

L. Moldawer, S. Lowry, C. S. Rock, 1992, The American journal of physiology.

Discovery of a Novel Cabazitaxel Nanoparticle-Drug Conjugate (CRLX522) with Improved Pharmacokinetic Properties and Anticancer Effects using a β-Cyclodextrin-PEG Copolymer-Based Delivery Platform.

S. Eliasof, S. Svenson, S. Tripathi, 2019, Journal of medicinal chemistry.

Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.

R. Kerbel, S. Eliasof, Christina R. Lee, 2016, Cancer research.